KDNY News and Press, Chinook Therapeutics Inc Com From 11/10/22

Chinook Therapeutics press release ( NASDAQ: KDNY ): Q3 GAAP EPS of -$0.83 misses by $0.20 . Revenue of $2.5M beats by $2.38M . For further details see: Chinook Therapeutics GAAP EPS of -$0.83 misses by $0.20, revenue of $2.5M beats by $2.38M

SEATTLE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the q...

The initial response to de novo subcutaneous (SC) BION-1301 treatment in Cohort 2 is highly consistent with Cohort 1 across both mechanistic biomarkers and proteinuria reductions BION-1301 is well-tolerated, with no serious adverse events (SAEs) and no treatment discontinu...

Atrasentan was well-tolerated with no treatment-related serious adverse events (SAEs) Atrasentan demonstrated mean proteinuria reductions of 38.1% proteinuria at six weeks of treatment, 48.3% at 12 weeks of treatment and 54.7% at 24 weeks of treatment T...

Updated interim data to be presented from the IgA nephropathy (IgAN) patient cohort of the atrasentan phase 2 AFFINITY basket trial Additional interim data to be presented from Cohorts 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgAN Rese...

Summary The key catalyst for Travere in the near term is the PDUFA date for sparsentan for the treatment of IgA nephropathy in early November. With a positive outcome anticipated, there might not be enough reward to hold the stock into the event. Given the recent slow launches...

Summary Shares have risen by 67% since May 2021 IPO. IgA Nephropathy is an increasingly attractive opportunity that multiple companies are targeting given regulatory tailwinds. Atacicept's unique value proposition is to target IgAN upstream (turn off the faucet) and strong obs...

Summary Shares have risen by 50% since coming public via reverse merger in 2020. Lead drug atrasentan has shown promising reductions in proteinuria that exceed approved treatment Tarpeyo. Competition in IgAN should not be underestimated from the likes of Travere Therapeutics, ...

Chinook Therapeutics press release ( NASDAQ: KDNY ): Q2 GAAP EPS of -$0.61 in-line. Revenue of $0.42M (+1300.0% Y/Y) in-line. For further details see: Chinook Therapeutics GAAP EPS of -$0.61 in-line, revenue of $0.42M in-line

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the q...